Indian IPOs Week of June 5: Five Issues, What to Know

Five companies open their subscription windows this week — one mainboard giant, one mainboard micro-cap, and three SME listings — as India's primary market reopens after a relative lull. The week spans aluminium recycling, clinical nutrition, AI analytics, textile chemicals, and B2B travel technology: a cross-section wide enough to tell you something about where promoters currently believe valuations will hold.

Here is what retail investors need to know about each issue, stripped of the noise.

---

The Weekly Lineup at a Glance

Issuer	Board	Issue Size (₹ cr)	Price Band (₹)	Open – Close	Listing Date	Lead Managers	Sector
CMR Green Technologies	Mainboard	630.88	182 – 192	Jun 3 – 5	Jun 10 (NSE, BSE)	Equirus Capital, ICICI Securities, Motilal Oswal Investment Advisors	Non-ferrous metal recycling
Hexagon Nutrition	Mainboard	138.87	42 – 45	Jun 5 – 9	Jun 12 (NSE, BSE)	Cumulative Capital, Catalyst Capital Partners	Clinical nutrition / premixes
Genxai Analytics	SME	54.84	110 – 116	Jun 5 – 9	Jun 12 (NSE SME)	Choice Capital Advisors	AI / enterprise analytics
UHM Vacation	SME	36.02	157 – 166	Jun 4 – 8	Jun 11 (BSE SME)	Sobhagya Capital Options	B2B travel aggregation
Vahh Chemicals	SME	13.45	60 (fixed)	Jun 4 – 8	Jun 11 (BSE SME)	Marwadi Chandarana Intermediaries	Textile auxiliary chemicals

Note: CMR Green subscription closed June 5; data included as it remained live through the week's opening day. All dates are tentative pending SEBI/exchange confirmation.

---

CMR Green Technologies: India's Aluminium Recycling Giant Goes Public

CMR Green Technologies describes itself as India's largest non-ferrous metal recycler by revenue and installed capacity — roughly four times that of its nearest domestic competitor, according to the company's own prospectus disclosures. It operates 13 recycling facilities with a combined production capacity of 6,15,150 MTPA as of March 2026, and holds an estimated 42–45% market share in the cast alloy automotive segment.

The core product is secondary aluminium: scrap goes in, aluminium alloy ingots, liquid aluminium alloys, and zinc alloy ingots come out. The company's differentiated offering is hot liquid aluminium delivered in insulated containers directly to die-casting lines — saving customers energy and remelting time. Major customers include Honda Cars India, Bajaj Auto, Hero MotoCorp, and Royal Enfield. Liquid aluminium and alloy ingots together accounted for over 81% of revenue in the nine months ended December 2025, per the RHP.

Red flags worth scrutinising:

• The IPO is a 100% Offer for Sale at ₹630.88 crore. Every rupee raised goes to exiting promoters; the company receives nothing. There is no capacity expansion or debt paydown funded by this issue.
• Top-10 customers account for roughly 50% of revenue. Automotive OEM demand is cyclical, and any production cutbacks by large OEMs flow directly to CMR's order book.
• The company reported a significant loss in FY24 (approximately ₹838 crore), before recovering. The source and reversal of that loss warrant scrutiny against the RHP.
• At the upper band of ₹192, the post-IPO P/E is approximately 19x and P/B approximately 9x — not negligible for a commodity-adjacent, working-capital-intensive business exposed to scrap price volatility.
• Technology partnerships with Toyota Tsusho, Nikkei MC Aluminium, and Nippon Light Metal add credibility but do not reduce margin exposure to raw material cycles.

The issue was subscribed approximately 9.59 times by Day 2 (Business Standard, June 4, 2026), suggesting institutional appetite. Retail interest is a separate question — and oversubscription does not guarantee a listing at a premium.

---

Hexagon Nutrition: Clinical Nutrition With a Pure-OFS Structure

Hexagon Nutrition makes micronutrient premixes, clinical supplements, and therapeutic food products, operating across three segments: B2B premix formulations (approximately 51% of 9MFY26 revenue), branded clinical nutrition sold under Pentasure, Obesigo, and Pediagold (approximately 30%), and international nutrition programmes. The company exports to over 75 countries and derived roughly 61% of FY25 revenue from exports.

Financials show genuine improvement: revenue from operations rose from ₹278.5 crore in FY23 to ₹324.9 crore in FY25, while profit after tax grew from ₹5.82 crore to ₹24.38 crore over the same period — margins expanding meaningfully. For 9MFY26, the pace has continued.

The price band is ₹42–₹45 per share (face value ₹1), placing the market cap at listing in the vicinity of ₹1,400–₹1,450 crore at the upper band.

Red flags worth scrutinising:

• Like CMR Green, this is a 100% OFS of 3.09 crore equity shares. The company raises zero capital from this IPO. Growth will be funded from internal accruals or future borrowing.
• Export dependency at approximately 61% of revenue means foreign exchange risk runs through the business. A sharp rupee appreciation or a trade dispute in key African or Asian markets could affect revenue recognition.
• The premix formulations segment is subject to ingredient pricing pressure; no long-term supply contracts were disclosed in public summaries of the RHP.
• Customer concentration risk: specific customer contribution figures are not publicly summarised, but dependence on a small number of global FMCG buyers in the premix segment is a known industry characteristic.

The lead managers — Cumulative Capital Private Limited and Catalyst Capital Partners Private Limited — are boutique advisors, unlike the large domestic banks that underwrite mainboard issues. That is not inherently problematic, but investors should factor in the likely depth of institutional distribution.

---

Genxai Analytics: AI Enterprise Software, SME Platform

Genxai Analytics offers enterprise technology services across EPM (Enterprise Performance Management), ERP, data engineering, generative AI, and web development. Over 50% of its revenue originates from outside India — the Americas account for 47.16% of revenue — giving it offshore exposure that most SME listings lack.

Revenue grew from ₹24.21 crore in FY24 to ₹28.88 crore in FY25, with PAT moving from ₹2.65 crore to ₹6.55 crore. For 9MFY26 (nine months to December 2025), standalone revenue came in at ₹64.27 crore and PAT at ₹13.31 crore — a pace that annualises to over ₹85 crore in revenue for FY26. The issue is a 100% fresh issue of 47.28 lakh shares at ₹110–₹116, raising ₹54.84 crore.

Red flags worth scrutinising:

• The BFSI vertical and the Americas concentration mean a slowdown in US financial services technology spend — or a large client churn — could materially affect numbers.
• At ₹54.84 crore for a company reporting roughly ₹85 crore annualised revenue, the implied price-to-sales ratio at listing will depend on which FY26 number is used; investors should verify this against the DRHP financials on the SEBI website.
• Generative AI advisory is a crowded, low-moat space; Genxai's differentiation rests on established EPM client relationships rather than proprietary AI models.
• SME listings have lower disclosure obligations and liquidity than mainboard issuances. Lock-ups on promoter shares and post-listing float are worth checking.

The registrar is Bigshare Services Private Limited.

---

UHM Vacation: B2B Travel Aggregator Betting on Outbound India

UHM Vacation operates an asset-light B2B digital platform connecting travel agents, corporate managers, and tour operators with airlines, hotels, cruise lines, car rentals, and visa facilitators via API/XML integrations and Global Distribution Systems. The Dubai and Gulf corridor drives a disproportionate share of bookings — international operations contributed 69.62% of revenue in FY25, with GCC markets as the primary engine.

Revenue has grown from ₹20.49 crore in FY23 to ₹40.20 crore in FY25 (approximately 31% CAGR), and the company carries near-zero debt. PAT is disclosed at ₹7.18 crore for FY25. The issue at ₹157–₹166 raises ₹36.02 crore (₹29.04 crore fresh, ₹6.97 crore OFS) and lists on BSE SME.

Red flags worth scrutinising:

• The B2B travel aggregation model is inherently margin-thin and faces structural pressure from suppliers cutting out intermediaries. Platform stickiness depends on whether agents have genuinely adopted UHM's interface as their primary booking tool.
• GCC concentration is a dual-edged proposition: Indian outbound travel to the Gulf is structural, but geopolitical disruption or a Gulf recession could compress volumes sharply.
• Day 2 subscription data showed the issue was subscribed approximately 0.28 times (HDFCSky, citing live subscription data), indicating subdued retail and non-institutional interest at the point of writing.
• The relatively small OFS component (₹6.97 crore) is less alarming than a majority-OFS, but retail investors should map fresh-issue proceeds against stated use: working capital and general corporate purposes.

The registrar is MUFG Intime India Private Limited.

---

Vahh Chemicals: Textile Auxiliary Chemicals, Surat Concentration

Vahh Chemicals manufactures and trades textile auxiliary chemicals — surface agents, softeners, wetting agents — used in pre-treatment, dyeing, printing, and finishing across the textile supply chain. As of September 2025, it offered 92 SKUs covering cotton, polyester, silk, and synthetic applications. The company's distribution is concentrated in Surat, India's largest synthetic textiles hub.

Revenue for FY26 stood at ₹43.19 crore, with PAT of ₹5.09 crore and EBITDA of ₹8.23 crore. The IPO is a 100% fresh issue of 22.42 lakh shares at a fixed price of ₹60, raising ₹13.45 crore. At ₹13.45 crore, this is the smallest issue of the five. Proceeds are earmarked for working capital (₹5.84 crore), a new Surat facility (₹1.84 crore), and debt repayment (₹1.79 crore).

Red flags worth scrutinising:

• The cost of materials consumed accounted for approximately 98.45% of operational revenue in FY26 — a figure that leaves almost no buffer for raw material price inflation or customer payment delays.
• No long-term supply contracts are disclosed. Textile auxiliary chemical inputs are petrochemical derivatives; any crude oil or import duty shock could immediately compress or eliminate margins.
• The minimum retail application is 4,000 shares, totalling ₹2,40,000 — substantially higher than the typical ₹15,000–₹20,000 lot seen in larger SME issues. This concentrates risk and reduces liquidity in the retail book.
• Surat concentration creates both customer and geographic risk; a textile sector downturn in Gujarat has an outsized impact.
• A nutraceutical subsidiary (HSHS Nutraceuticals, "Divine Nutrition" brand) adds diversification on paper, but contributes no material revenue at current scale.

---

What to Watch

Subscription data, not just GMP. Grey-market premiums are unregulated and have repeatedly proven poor predictors of listing price — particularly in 2026, when average listing gains for mainboard IPOs are running at approximately -1.9% (according to Chittorgarh's performance tracker). Watch actual subscription figures across QIB, HNI, and retail categories once windows close: QIB participation signals institutional conviction; retail oversubscription without QIB following is not a corroborating signal.

OFS-heavy structures this week. Both mainboard issues — CMR Green (100% OFS) and Hexagon Nutrition (100% OFS) — transfer no capital to their respective companies. Investors in these issues are buying a stake from exiting shareholders, not funding growth. That is a structurally different proposition from a growth-focused fresh issue, and valuation discipline is accordingly more important.

CMR listing date is June 10. That comes before the Hexagon Nutrition and Genxai listings on June 12, and before UHM Vacation and Vahh Chemicals on June 11. CMR's opening day trade will provide a market read on institutional follow-through in the recycling and materials space.

Broader market context. The week of June 5 opens against a domestic market that has been cautiously constructive after the RBI's June 2026 rate decision (covered in article 104 on this site). Retail participation in IPOs broadly has softened in 2026 relative to the 2024 peak; approximately 66% of 2026 listings were trading below issue price at the time of writing, per available tracker data. That context does not make this week's issues bad or good — it makes due diligence more consequential than the GMP headline.

Read the RHP. SEBI mandates full prospectus disclosure. The RHP for each of these issues is publicly available on the SEBI website and on the NSE/BSE document portals. Risk factors are listed verbatim, and investors should not rely on third-party summaries — including this one — as a substitute for primary document review.

---

This article is for informational purposes only and does not constitute investment advice. IPO investments carry market, valuation, and liquidity risk. Consult a SEBI-registered investment adviser before making any investment decision.